The European Commission has approved Sanofi SA's (NASDAQ: SNY) Aubagio (teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting...
The European Commission ((EC)) has approvedSanofi companyGenzyme'sAubagio(teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting...
The FDA has approved Sanofi SA's (NASDAQ: SNY) newly completed plant in Swiftwater, Pennsylvania.The license will allow Sanofi to begin production of ...Full story available on...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Sell | Buy | Strong Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Buy | Strong Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,402.22 | 2,432.06 | 2,400.30 | -32.65 | -1.34% | 2.31M | NASDAQ | |||
| 329.66 | 336.15 | 329.00 | -6.85 | -2.04% | 23.04M | NASDAQ | |||
| 59.26 | 64.96 | 56.85 | -1.47 | -2.42% | 243.65M | NYSE | |||
| 115.79 | 117.89 | 115.21 | -3.33 | -2.80% | 12.53M | NYSE | |||
| 212.30 | 213.84 | 210.59 | +0.70 | +0.33% | 13.72M | NYSE | |||
| 16.02 | 16.66 | 16.02 | -0.31 | -1.90% | 11.54M | NYSE | |||
| 16.82 | 17.40 | 16.79 | -0.71 | -4.05% | 7.77M | NASDAQ | |||
| 73.54 | 74.48 | 73.09 | -0.19 | -0.26% | 250.68K | NYSE | |||
| 96.22 | 97.98 | 96.22 | -3.08 | -3.10% | 595.53K | NYSE | |||
| 8.22 | 8.43 | 8.18 | -0.39 | -4.53% | 11.54M | NYSE | |||
| 17.53 | 17.59 | 17.28 | +0.09 | +0.52% | 32.46K | NYSE | |||
| 17.83 | 18.34 | 17.66 | -0.54 | -2.94% | 1.46M | NASDAQ | |||
| 6.17 | 6.20 | 6.12 | -0.19 | -2.99% | 2.09M | NYSE | |||
| 10.17 | 10.34 | 10.13 | -0.25 | -2.40% | 8.48M | NYSE | |||
| 127.83 | 128.00 | 124.50 | +0.56 | +0.44% | 1.24M | NASDAQ |
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
